AGY Therapeutics is a leading company dedicated to pioneering breakthrough treatments for central nervous system diseases through innovative gene discovery and pathway mapping. Founded in 1998, the company is focused on the discovery, development, and commercialization of groundbreaking treatments for diseases affecting the central nervous system. AGY has a robust pipeline of innovative CNS therapeutic programs at both clinical and preclinical stages, addressing significant unmet medical needs.
The company has established its pipeline through a proprietary platform for functional gene discovery and mapping specific pathways associated with central nervous system diseases. By leveraging these capabilities, AGY has identified potential target proteins that can be modulated to halt disease progression. This approach is setting the stage for new CNS therapeutics and future growth for AGY in the Biopharma, Biotechnology, and Health and Wellness industries.
AGY Therapeutics received a notable $9.00M Series C investment on 07 August 2004, attracting investments from an impressive array of investors, including JAFCO Japan, Novartis Venture Fund, Alta Partners, GE Capital, GIMV, HBM Partners, Bear Stearns Health Innoventures L.P, Cheng Xin Technology Development Corp. This infusion of capital underscores the confidence of industry leaders in AGY's potential to make significant strides in the treatment of central nervous system diseases.
